Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Long-Term Investments: 2010-2022

Historic Long-Term Investments for Arrowhead Pharmaceuticals (ARWR) over the last 9 years, with Sep 2022 value amounting to $105.9 million.

  • Arrowhead Pharmaceuticals' Long-Term Investments fell 74.20% to $42.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was $42.8 million, marking a year-over-year decrease of 74.20%. This contributed to the annual value of $105.9 million for FY2022, which is 56.89% down from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Long-Term Investments stood at $105.9 million for FY2022, which was down 56.89% from $245.6 million recorded in FY2021.
  • Arrowhead Pharmaceuticals' Long-Term Investments' 5-year high stood at $245.6 million during FY2021, with a 5-year trough of $44.2 million in FY2019.
  • Its 3-year average for Long-Term Investments is $163.0 million, with a median of $137.5 million in 2020.
  • Its Long-Term Investments has fluctuated over the past 5 years, first spiked by 211.23% in 2020, then tumbled by 56.89% in 2022.
  • Over the past 4 years, Arrowhead Pharmaceuticals' Long-Term Investments (Yearly) stood at $44.2 million in 2019, then spiked by 211.23% to $137.5 million in 2020, then soared by 78.63% to $245.6 million in 2021, then plummeted by 56.89% to $105.9 million in 2022.